Evogene
Evogene
EVGN
NASDAQ
3.29
USD
155.04%
About
Evogene Ltd is an Israel-based company, engaged in leveraging computational biology to design products for life-science-based industries including human health, agriculture, and industrial applications. Leveraging Big Data and Artificial Intelligence while incorporating a deep understanding of biology, Evogene established its technology, the Computational Predictive Biology (CPB) platform, to computationally design microbes, small molecules and genes as the core components for life-science products.
Evogene holds a number of subsidiaries utilizing the CPB platform, for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil production..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 39.4K |
| Three Month Average Volume | 450.4K |
| High Low | |
| Fifty-Two Week High | 10.4 USD |
| Fifty-Two Week Low | 3.25 USD |
| Fifty-Two Week High Date | 04 Mar 2024 |
| Fifty-Two Week Low Date | 30 Aug 2024 |
| Price and Volume | |
| Current Price | 3.29 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -35.66% |
| Thirteen Week Relative Price Change | -58.74% |
| Twenty-Six Week Relative Price Change | -69.47% |
| Fifty-Two Week Relative Price Change | -64.53% |
| Year-to-Date Relative Price Change | -66.93% |
| Price Change | |
| One Day Price Change | -2.37% |
| Thirteen Week Price Change | -55.84% |
| Twenty-Six Week Price Change | -66.43% |
| Five Day Price Change | -15.21% |
| Fifty-Two Week Price Change | -55.56% |
| Year-to-Date Price Change | -60.83% |
| Month-to-Date Price Change | -31.88% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 2.38273 USD |
| Book Value Per Share (Most Recent Quarter) | 0.60175 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | -0.22062 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | -1.88708 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -3.75254 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 1.23452 USD |
| Revenue Per Share (Trailing Twelve Months) | 1.87935 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -5.22681 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -3.94496 USD |
| Normalized (Last Fiscal Year) | -5.22909 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -5.22681 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -3.94496 USD |
| Including Extraordinary Items (Last Fiscal Year) | -5.22681 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -3.94496 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 6.14077 USD |
| Cash Per Share (Most Recent Quarter) | 4.10221 USD |
| Cash Flow Per Share (Last Fiscal Year) | -5.10927 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -3.66303 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -4.03377 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -1,111 |
| Cash Flow Revenue (Trailing Twelve Months) | -215 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -222.60% |
| Pretax Margin (Last Fiscal Year) | -460.76% |
| Pretax Margin (5 Year) | -1,309.40% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -42.57% |
| Gross Margin (Trailing Twelve Months) | 81.42% |
| Gross Margin (5 Year) | -117.65% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -470.00% |
| Operating Margin (Trailing Twelve Months) | -227.27% |
| Operating Margin (5 Year) | -1,333.75% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -460.18% |
| Net Profit Margin (Trailing Twelve Months) | -222.51% |
| Net Profit Margin (5 Year) | -1,310.66% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -34.28% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 39.76% |
| Revenue Growth (3 Year) | 26.41% |
| Revenue Change (Trailing Twelve Months) | 290.29% |
| Revenue Per Share Growth | 12.72% |
| Revenue Growth (5 Year) | 75.69% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 15.98% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 36.88% |
| EPS Change (Trailing Twelve Months) | 28.44% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -9,706,000 |
| Net Debt (Last Fiscal Year) | -19,557,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 3 |
| Price to Sales (Trailing Twelve Months) | 2 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 5 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 88 |
| Long Term Debt to Equity (Most Recent Quarter) | 347 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 5 |
| Quick Ratio (Most Recent Quarter) | 4 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 5 |
| Current Ratio (Most Recent Quarter) | 4 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -22,362,000 |
| Free Cash Flow (Trailing Twelve Months) | -20,281,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 95 |
| Total Debt to Equity (Most Recent Quarter) | 365 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -48.41% |
| Return on Assets (Trailing Twelve Months) | -44.59% |
| Return on Assets (5 Year) | -39.79% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -119.45% |
| Return on Equity (Trailing Twelve Months) | -228.95% |
| Return on Equity (5 Year) | -57.37% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -72.94% |
| Return on Investment (Trailing Twelve Months) | -87.01% |
| Return on Investment (5 Year) | -52.52% |